Abstract:Over the past two decades, immunotherapies have increasingly been considered as first-line treatments for most cancers. One such treatment is immune checkpoint blockade (ICB), which has demonstrated promising results against various solid tumors in clinical trials. Monoclonal antibodies (mAbs) are currently available as immune checkpoint inhibitors (ICIs). These ICIs target specific immune checkpoints, including cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1). Clinical trial results strongly support the feasibility of this immunotherapeutic approach. However, a substantial proportion of patients with cancer develop resistance or tolerance to treatment, owing to tumor immune evasion mechanisms that counteract the host immune response. Consequently, substantial research focus has been aimed at identifying additional ICIs or synergistic inhibitory receptors to enhance the effectiveness of anti-PD-1, anti-programmed cell death ligand 1 (anti-PD-L1), and anti-CTLA-4 treatments. Recently, several immune checkpoint molecular targets have been identified, such as T cell immunoreceptor with Ig and ITIM domains (TIGIT), mucin domain containing-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), V-domain immunoglobulin suppressor of T cell activation (VISTA), B and T lymphocyte attenuator (BTLA), and signal-regulatory protein α (SIRPα). Functional mAbs targeting these molecules are under development. CTLA-4, PD-1/PD-L1, and other recently discovered immune checkpoint proteins with distinct structures are at the forefront of research. This review discusses these structures, as well as clinical progress in mAbs targeting these immune checkpoint molecules and their potential applications.

Immune Checkpoint Blockade and Its Combination Therapy with Small-Molecule Inhibitors for Cancer Treatment

Tumor Immune Checkpoints and Their Associated Inhibitors

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

Immune Checkpoint Inhibitors Combined with Targeted Therapy: the Recent Advances and Future Potentials

Immune checkpoint inhibitors: breakthroughs in cancer treatment

Development of small molecule drugs targeting immune checkpoints

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment

The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment

Emerging immune checkpoint and its combination therapy in cancer treatment

Immune checkpoint blockade in the treatment of malignant tumor: current statue and future strategies

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment

Small Molecule- and Peptide-Based Approaches

Immune Checkpoint Inhibitors' challenges, mechanisms and management

Metabolic Interventions Combined with CTLA-4 and PD-1/PD-L1 Blockade for the Treatment of Tumors: Mechanisms and Strategies.

Immune checkpoint signaling and cancer immunotherapy

[Integration of cell function into functioning of the organism].

Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy

Liposome-based nanomedicine for immune checkpoint blocking therapy and combinatory cancer therapy

Aptamer‐based Immune Checkpoint Inhibition for Cancer Immunotherapy

Novel Combination Strategies to Enhance Immune Checkpoint Inhibition in Cancer Immunotherapy: A Narrative Review